Drug Trial Radar · NCT01464905
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Last checked: Nov 20, 2026Latest source record: Sep 23, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Oct 2011
Primary completion
Dec 2013
Study completion Dec 2014
Sponsor
- Lead sponsor
- Nuron Biotech Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of NU100 in patients with relapsing remitting multiple sclerosis (RRMS) as compared to placebo and an active comparator. The primary clinical objective selected for this Phase 3 study, the cumulative number of new combined unique active lesions (CALs; defined as new gadolinium T1-weighted lesions and non-enhancing new and newly enlarging T2-weighted lesions) on magnetic resonance imaging (MRI) scans over the course of 4 and 12 months of treatment to demonstrate the superiority of NU100 to placebo and the non-inferiority of NU100 to Betaferon®, respectively.
Conditions
- Relapsing Remitting Multiple Sclerosis
Interventions
NU100Biological
0.25 mg SQ, every other day for 12 months
PlaceboBiological
1 mL SQ, every other day for 4 months
rhIFN beta-1bBiological
0.25 mg SQ, every other day for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- New CALs after 4 months of treatment based on the MRI outcomes obtained at 4 and 12 monthsTime frame: 2 to 12 months
Locations
12 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Minsk, Belarus
Site not named
Sofia, Bulgaria
Site not named
Zagreb, Croatia
Site not named
Tbilisi, Georgia
Site not named
Budapest, Hungary
Site not named
Rome, Italy
Site not named
Beirut, Lebanon
Site not named
Warsaw, Poland
Site not named
Moscow, Russia
Site not named
Belgrade, Serbia
Site not named
Barcelona, Spain
Site not named
Kiev, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.